Pim kinase inhibitors in cancer: medicinal chemistry insights into their activity and selectivity
Related Experiment Video
Updated: Dec 7, 2025

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Soraya Alnabulsi1, Enas A Al-Hurani1
1Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, PO Box 3030, Irbid 22110, Jordan.
Abstract:
The oncogenic Pim kinase proteins (Pim-1/2/3) regulate tumorigenesis through phosphorylating essential proteins that control cell cycle and proliferation. Pim kinase is a potential chemotherapeutic target in cancer and its inhibition is currently the focus of intensive drug design and development efforts. The distinctive presence of proline amino acids in the hinge region provides an opportunity to inhibit Pim kinase while conserving the physiological functions of other kinases and reducing the toxicity profiles of the inhibitors. Various Pim kinase inhibitors have been clinically evaluated for the treatment of hematological cancers, yet none has reached the clinic. In this review, we discuss the design and development of selective and potent Pim inhibitors with novel chemotypes focusing on structural features essential for high potency and selectivity.
Insights
Selective inhibition of oncogenic Pim kinases (Pim-1/2/3) offers a promising cancer therapy strategy. Targeting the unique proline-rich hinge region allows for potent and safe Pim kinase inhibitors, advancing cancer drug development.
Area of Science:
- Oncology
- Medicinal Chemistry
- Molecular Biology
Background:
- Pim kinase proteins (Pim-1/2/3) are oncogenic, regulating cell cycle and proliferation via phosphorylation.
- Pim kinase is a validated chemotherapeutic target, with inhibitors under intensive drug design and development.
- Existing inhibitors have shown promise in hematological cancers but none have reached clinical approval.
Purpose of the Study:
- To review the design and development of selective and potent Pim kinase inhibitors.
- To focus on novel chemotypes and structural features crucial for high potency and selectivity.
- To explore strategies for inhibiting Pim kinase while preserving other kinase functions and reducing toxicity.
Main Methods:
- Review of published literature on Pim kinase inhibitor design and development.
- Analysis of structural features, particularly the proline-rich hinge region, for selective inhibition.
- Discussion of novel chemotypes and their structure-activity relationships.
Main Results:
- The proline-rich hinge region of Pim kinases presents a unique opportunity for selective inhibitor design.
- Novel chemotypes have been developed with improved potency and selectivity profiles.
- Despite clinical evaluations, challenges remain in bringing Pim kinase inhibitors to market.
Conclusions:
- Selective Pim kinase inhibition is a viable strategy for cancer therapy.
- Understanding structural features is key to developing effective and safe Pim inhibitors.
- Further research into novel chemotypes and clinical translation is warranted.
Related Concept Videos
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
PI3K/mTOR/AKT Signaling Pathway

